[
    [
        {
            "time": "2021-10-30",
            "original_text": "药明康德2021年三季报点评：业绩略超市场预期，新业务拓展具有显著成果【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "药明康德",
                    "三季报",
                    "业绩",
                    "新业务",
                    "东吴医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德2021年三季报点评：业绩略超市场预期，新业务拓展具有显著成果【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "信达证券发布药明康德研报，公司点评报告：业绩稳健高增长，CDMO 龙头强者恒强",
            "features": {
                "keywords": [
                    "信达证券",
                    "药明康德",
                    "研报",
                    "业绩",
                    "CDMO",
                    "龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信达证券发布药明康德研报，公司点评报告：业绩稳健高增长，CDMO 龙头强者恒强",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "港股异动 | 药明康德(02359)跌超7%领跌医药生物股 机构继续减仓，情绪临近冰点",
            "features": {
                "keywords": [
                    "港股",
                    "药明康德",
                    "下跌",
                    "医药生物",
                    "减仓",
                    "情绪"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股异动 | 药明康德(02359)跌超7%领跌医药生物股 机构继续减仓，情绪临近冰点",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "东吴证券：维持药明康德(603259.SH)“买入”评级 CDMO业务驱动业绩增长",
            "features": {
                "keywords": [
                    "东吴证券",
                    "药明康德",
                    "买入评级",
                    "CDMO",
                    "业绩增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券：维持药明康德(603259.SH)“买入”评级 CDMO业务驱动业绩增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "图解药明康德三季报：第三季度单季净利润同比增36.23%",
            "features": {
                "keywords": [
                    "药明康德",
                    "三季报",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "图解药明康德三季报：第三季度单季净利润同比增36.23%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "中航证券维持药明康德买入评级：业绩高速增长，“长尾”战略持续发力",
            "features": {
                "keywords": [
                    "中航证券",
                    "药明康德",
                    "买入评级",
                    "业绩增长",
                    "长尾战略"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中航证券维持药明康德买入评级：业绩高速增长，“长尾”战略持续发力",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "药明康德前三季净利增五成 完成定制化化合物合成20万个",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利增长",
                    "定制化化合物",
                    "合成"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德前三季净利增五成 完成定制化化合物合成20万个",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-30",
            "original_text": "港股异动︱药明康德(02359)早盘高开4.27% 前三季度归母净利同比增长50.41%至35.62亿元",
            "features": {
                "keywords": [
                    "港股",
                    "药明康德",
                    "高开",
                    "净利增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动︱药明康德(02359)早盘高开4.27% 前三季度归母净利同比增长50.41%至35.62亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]